ArticleTherapeutic advances in gastroenterology2010
Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.
Article in Therapeutic advances in gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05382351 (Exploratory Study on Antiviral Therapy for Patients With Chronic Hepatitis B Virus Infection), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploratory Study on Antiviral Therapy for Patients With Chronic Hepatitis B Virus Infection (Immune Tolerance Period)
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Pooled it
- Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients.Drug design, development and therapy · 2022Trial
- Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B.Clinical and molecular hepatology · 2017Trial
- Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation.Antimicrobial agents and chemotherapy · 2015Trial
- Relative bioavailability study of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy male fasted volunteers.Clinical drug investigation · 2012Trial
- Higher Rates of Viral Evolution in Chronic Hepatitis B Patients Linked to Predicted T Cell Epitopes.Viruses · 2025Article
- Effect of nucleos(t)ide analogue discontinuation on the prognosis of HBeAg-negative hepatitis B virus-related hepatocellular carcinoma after hepatectomy: A propensity score matching analysis.Cancer medicine · 2024Article
- Degradants of Tenofovir Disoproxil Fumarate Under Forced Yet Mild Thermal Stress: Isolation, Comprehensive Structural Elucidation, and Mechanism.AAPS PharmSciTech · 2023Article
- HIV-HBV Coinfection-Current Challenges for Virologic Monitoring.Biomedicines · 2023Review
- Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity.Molecular biomedicine · 2022Review
- Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients.Journal of clinical medicine · 2022Article
- Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop.Clinical and molecular hepatology · 2020Review
- Overview of Biologically Active Nucleoside Phosphonates.Frontiers in chemistry · 2020Review
- Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate.Medicine · 2019Article
- Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate.Gut and liver · 2019Article
- Pathologic femoral fracture due to tenofovir-induced Fanconi syndrome in patient with chronic hepatitis B: A case report.Medicine · 2017Article
- Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases.Clinical and molecular hepatology · 2016Article
- The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists.Journal of nephrology · 2015Review
- Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.Clinical and molecular hepatology · 2014Article
- A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.BMC health services research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B (CHB) is prevalent worldwide. It may cause cirrhosis and hepatocellular carcinoma. Treatment for this condition may need to be lifelong, thus the drugs used must be both efficacious and safe. Clinical trials of tenofovir have demonstrated a good safety profile for this drug and it has potent antiviral properties. However, to better characterize the safety of this drug, the postmarketing surveillance must be taken into account. Clinicians need to be vigilant, as infrequent adverse events may be revealed during this phase. The current review presents a detailed exposé of preclinical and clinical data on tenofovir to increase awareness of possible adverse events and drug-drug interactions, based on the large experience of this drug in human immunodeficiency virus (HIV) treatment (and to date in patients with CHB). Several recommendations that may help the clinician to prevent the development of adverse events associated with tenofovir disoproxil fumarate (TDF) treatment are outlined, along with a suggested surveillance protocol for the timely and proper identification of possible renal and bone toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.